ONCY logo

ONCY
Oncolytics Biotech, Inc.

7,539
Mkt Cap
$96.62M
Volume
306,006.00
52W High
$1.51
52W Low
$0.3258
PE Ratio
-3.22
ONCY Fundamentals
Price
$0.8251
Prev Close
$0.8095
Open
$0.8199
50D MA
$0.9397
Beta
0.93
Avg. Volume
1.31M
EPS (Annual)
-$0.30
P/B
-18.32
Rev/Employee
$0.00
$79.14
Loading...
Loading...
News
all
press releases
Penny Stock Oncolytics Biotech Says Colorecatal Cancer Drug's Durability Tops Historical Benchmarks
Oncolytics shares rise as pelareorep shows 19.5-month response durability and higher response rates in colorectal cancer study.read more...
News Placeholder
More News
News Placeholder
Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Rating of "Moderate Buy" by Analysts
Shares of Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) have received an average rating of "Moderate Buy" from the five brokerages that are currently covering the firm, MarketBeat reports...
News Placeholder
Q1 EPS Forecast for Oncolytics Biotech Lifted by Analyst
Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Equities research analysts at HC Wainwright upped their Q1 2026 EPS estimates for Oncolytics Biotech in a research note issued on Friday, April 10th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.03) per share f...
News Placeholder
Equities Analysts Issue Forecasts for ONCY Q1 Earnings
Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Stock analysts at HC Wainwright issued their Q1 2027 EPS estimates for Oncolytics Biotech in a report released on Friday, April 10th. HC...
News Placeholder
Q1 Earnings Estimate for ONCY Issued By Zacks Research
Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Zacks Research issued their Q1 2026 earnings estimates for shares of Oncolytics Biotech in a note issued to investors on Tuesday, April 7th...
News Placeholder
What is Zacks Research's Forecast for ONCY FY2026 Earnings?
Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Equities research analysts at Zacks Research issued their FY2026 earnings per share estimates for Oncolytics Biotech in a research note issued to...
News Placeholder
Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Consensus Rating of "Moderate Buy" from Analysts
Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) has been given an average rating of "Moderate Buy" by the five research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two...
News Placeholder
Oncolytics Biotech (NASDAQ:ONCY) Upgraded to Hold at Wall Street Zen
Wall Street Zen upgraded shares of Oncolytics Biotech from a "strong sell" rating to a "hold" rating in a research report on Saturday...
News Placeholder
Oncolytics Biotech (NASDAQ:ONCY) Releases Earnings Results, Misses Expectations By $0.02 EPS
Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by...
News Placeholder
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care PR Newswire VANCOUVER, BC, March 19, 2026...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available